Stocktoria
BIO-RAD LABORATORIES, INC. BIO
BIO-RAD LABORATORIES, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.7B | $2.8B | $2.9B | $2.5B | $2.3B | $2.3B | $2.2B | $2.1B |
| Gross profit | $1.3B | $1.4B | $1.4B | $1.6B | $1.6B | $1.4B | $1.3B | $1.2B | $1.2B | $1.1B |
| R&D expense | $275.6M | $295.9M | $247.4M | $256.9M | $260.6M | $217.8M | $202.7M | $199.2M | $250.2M | $205.7M |
| SG&A expense | $844.3M | $814.0M | $841.7M | $827.8M | $877.1M | $798.8M | $824.6M | $834.8M | $806.8M | $814.7M |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M | $421.3M | $229.7M | -$103.3M | $119.2M | $55.7M |
| Interest expense | $49.0M | $48.9M | $49.4M | $38.1M | $1.6M | $21.9M | $23.4M | $24.0M | $23.0M | $23.4M |
| Income tax | $235.6M | -$498.3M | -$212.8M | -$1.1B | $1.2B | $1.1B | $502.4M | $147.0M | -$24.4M | $15.6M |
| Net income | $759.9M | -$1.8B | -$637.3M | -$3.6B | $4.3B | $3.8B | $1.8B | $365.6M | $122.2M | $26.0M |
| EPS (diluted) | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 | $126.47 | $58.27 | $12.10 | $4.07 | $0.88 |
| Operating cash flow | $532.2M | $455.2M | $374.9M | $194.4M | $669.5M | $585.0M | $457.9M | $285.5M | $104.1M | $216.1M |
| Free cash flow | $374.6M | $289.6M | $218.2M | $81.6M | $535.7M | $476.4M | $359.4M | $155.7M | -$7.2M | $74.6M |
| Cash & equivalents | $529.8M | $488.1M | $403.8M | $434.2M | $470.8M | $662.2M | $660.7M | $431.5M | $383.8M | $456.3M |
| Inventory | $740.7M | $760.0M | $780.5M | $719.3M | $572.2M | $622.3M | $554.0M | $583.8M | $594.8M | $525.0M |
| Total assets | $10.6B | $9.4B | $12.3B | $13.5B | $17.8B | $13.0B | $8.0B | $5.6B | $4.3B | $3.9B |
| Total liabilities | $3.1B | $2.8B | $3.6B | $3.9B | $4.1B | $3.1B | $2.3B | $1.6B | $1.3B | $1.3B |
| Shareholders' equity | $7.5B | $6.6B | $8.7B | $9.6B | $13.7B | $9.9B | $5.8B | $4.0B | $2.9B | $2.6B |
Growth · year-over-year · Revenue CAGR 2.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +0.7% | -3.9% | -4.7% | -4.1% | +14.8% | +10.1% | +1.0% | +6.0% | +4.4% | +2.4% |
| Net income growth | — | — | — | -185.3% | +11.5% | +116.9% | +381.0% | +199.1% | +370.2% | -76.2% |
| EPS growth | — | — | — | -186.5% | +11.4% | +117.0% | +381.6% | +197.3% | +362.5% | -76.3% |
| Free cash flow growth | +29.4% | +32.7% | +167.4% | -84.8% | +12.4% | +32.6% | +130.9% | — | -109.6% | +0.6% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.